Benjamin E Greer, MD
Professor
Director, SCCA Network
Director, SCCA Division of Gynecologic Oncology

• MD degree
   (University of Pennsylvania, 1966)
• Residency in Obstetrics and Gynecology
   (University of Colorado Medical Center, 1970)
• Certificate, Management Program
   (University of Washington School of Business Admin, 1991)

• American College of Obstetricians and Gynecologists
• American Gynecological and Obstetrical Society
• American Society of Clinical Oncology
• Association of Professors of Gynecology and Obstetrics
• Central Association of Obstetricians and Gynecologists
• Felix Rutledge Society
• Gynecologic Oncology Group (GOG)
• International Gynecologic Cancer Society
• King County Medical Society
• National Comprehensive Cancer Network
• North Dakota Society of Obstetrics and Gynecology (Honorary Member)
• Pacific Coast Obstetrical and Gynecological Society
• Puget Sound Oncology Consortium
• Society of Gynecologic Oncologists (SGO), Vice President
• Seattle Gynecological Society
• Washington State Medical Association
• Western Association of Gynecologic Oncologists (Past President)

Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelilal ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71.

Greer BE, Bundy BN, Ozols RF, Fowler MJ, Clarke-Pearson D, et al. Implications of second-look laparotomy in the context of optimally resected  stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;99(1)71-79.

Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG 182-ICON5. Int J Gynecol Cancer. 2003;13(6):735-40.

Koh WJ, Panwala K, Greer B. Adjuvant therapy for high-risk, early stage cervical caner. Sem Rad Oncol 2000;10:51–60.

Paley PJ, Goff BA, Minudri R, Greer BE, Tamimi HK, Koh WJ. The prognostic significance of radiation dose and residual tumor in the treatment of barrel-shaped endophytic cervical carcinoma. Gynecol Oncol 2000;76:373.

Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh WJ, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol 1999;74:436–442.

Grice J, Ek M, Greer BE, Koh W-J, Muntz HG, Cain JM, Tamimi HK, Stelzer K, Figge D, Goff BA. Uterine papillary serous carcinoma (UPSC): evaluation of long-term survival in 36 surgically staged patients. Gynecol Oncol 1998;69:69.

Greer BE, Koh W-J, Goff BA, Stelzer KJ, Corsic N, Tran A. Expanded customized pelvic radiotherapy fields for treatment of local-regionally advanced carcinoma of the cervix: outcome, complications, and future strategies. Am J Obstet & Gyn 1996;174:1141–1150.

Stelzer KJ, Koh WJ, Greer BE, Cain JM, Tamimi HK, Figge DC, Goff BA, Griffin TW. The use of intraoperative radiation therapy in radical salvage for recurrent cervix cancer: outcome and toxicity. Am J Obstet & Gyn 1995;172:1881-1888.

Koh WJ, Chiu M, Stelzer K, Greer B, Mastras C, Comsia N, Russell K, Griffin T. Femoral vessel depth and the implications for node radiation. Int J Radiation Oncology Biol Phys 1993;27:969.

Greer BE, Koh WJ, Figge DC, Russell AH, Cain JM, Tamimi HK. Gynecologic radiotherapy fields defined by intraoperative measurements. Gynecol Oncol 1990;38:421–424. Abstracted ACOG Current Journal Review 1991;4(2):55-56.

Greer BE, Cain JM, Figge DC, Shy KK, Tamimi HK. Supraumbilical upper abdominal midline incision for pelvic surgery in the morbidly obese patient. Obstet Gynecol 1990;76:471–473.

Greer BE, Easterling TR, McLennan DA, Benedetti TJ, Cain JM, Figge DC, Tamimi HK, Jackson JC. Fetal and maternal considerations of the management of stage IB cervicalcancer during pregnancy. Gynecol Oncol 1989;34:61–65.